Ebola Vaccine Trial Expansion Targets Bundibugyo

Which Ebola vaccines are being considered for the trial?

WHO's independent vaccine advisory group recommended the candidates after reviewing preclinical and early clinical evidence. Tumaini uses ring vaccination, enrolling contacts of confirmed cases, and already includes Ervebo. WHO expects vaccine findings in early 2027; this remains a projected timeline. [WHO announcement](https://www.who.int/brunei/news/detail-global/04-11-2026-two-new-candidate-vaccines-to-join-ebola-trial-as-treatment-research-advances)

The virus being targeted matters. Ebola disease can be caused by several distinct viruses, and a vaccine's effectiveness against one cannot automatically be assumed for another. WHO's vaccine guidance identifies Ervebo as a licensed vaccine against Ebola virus, historically called Zaire ebolavirus, while protection against Bundibugyo remains under investigation. Studying a vaccine during an outbreak can help establish whether it prevents clinical disease in exposed populations. [WHO vaccine guidance](https://www.who.int/news-room/questions-and-answers/item/ebola-vaccines)

Which treatments are being studied for Bundibugyo virus disease?

WHO also reports a separate post-exposure prevention study involving obeldevisir. These research programs address different questions: whether medicines improve survival after confirmed infection and whether treatment after exposure can prevent illness. The announcement does not report efficacy results. [WHO treatment research update](https://www.who.int/brunei/news/detail-global/04-11-2026-two-new-candidate-vaccines-to-join-ebola-trial-as-treatment-research-advances)

Earlier Ebola research provides a precedent for testing treatments rigorously. The PALM randomized trial enrolled 681 patients and compared four experimental therapies alongside standard care. Its findings favored the antibody treatments mAb114 and REGN-EB3 over ZMapp and remdesivir for mortality. However, PALM studied Ebola virus disease caused by the Zaire virus; those findings do not establish which treatment works against Bundibugyo. They also show why a medicine's antiviral activity alone is insufficient evidence of a survival benefit. [PALM trial, New England Journal of Medicine](https://www.nejm.org/doi/full/10.1056/NEJMoa1910993)

What does experimental Ebola research mean for patient care?

WHO emphasizes that early intensive supportive care improves survival. Treatment includes rehydration and management of symptoms and complications. In the earlier PALM trial, supportive care included fluid and electrolyte replacement, monitoring blood pressure and oxygen levels, and other treatments when needed. Experimental medicines are evaluated within this broader clinical care framework. [WHO Ebola disease fact sheet](https://www.who.int/news-room/fact-sheets/detail/ebola-disease) [NIH explanation of PALM care](https://www.nih.gov/news-events/nih-research-matters/two-drugs-reduce-risk-death-ebola)

Vaccination is also one part of outbreak control. WHO identifies laboratory testing, contact tracing, infection prevention and safe patient care as complementary measures. For readers assessing future trial announcements, the crucial distinction is between a candidate entering research and a treatment demonstrating benefit: clinical findings must establish what happened to participants, how outcomes compared, and what adverse effects occurred before conclusions about usefulness can be drawn. [WHO outbreak-control guidance](https://www.who.int/news-room/fact-sheets/detail/ebola-disease)